Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.
Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
The “Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
Scope of the Report
The “Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Amongst other elements, the report features:
- A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
- Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
- An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
- An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
- An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
- An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
- Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
- An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the key players engaged in the development of viral vaccine cell culture media?
- Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
- What type of partnership models are commonly adopted by stakeholders engaged in this industry?
- What is the relative competitiveness of different viral vaccine cell culture media?
- Who are the most likely partners for vaccine cell culture media developers?
- What are the key challenges currently faced by stakeholders in this industry?
- What are the anticipated future trends related to viral vaccine cell culture media developers?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY PROFILES
6. RECENT DEVELOPMENTS AND INITIATIVES
7. LIKELY PARTNER ANALYSIS
8. PRODUCT COMPETITIVENESS ANALYSIS
9. BRAND POSITIONING
10. PATENT ANALYSIS
11. DEMAND ANALYSIS
12. MARKET FORECAST
13. CONCLUSION
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2BScientific
- Adimmune
- Aduro Biotech
- Advagene Biopharma
- Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
- Advanced BioScience Laboratories
- Advent
- AJ Biologics
- Albany Molecular Research
- Alopexx Vaccine
- Altimmune
- Amphera
- Anhui Zhifei Longcom Biologic Pharmacy
- Applied Biosystems
- Argos Therapeutics
- Astellas Pharma
- Asterias Biotherapeutics
- ATZ labs
- Auro Vaccines
- Aurora Biopharma
- AVAX Technologies
- Avid Bioservices
- AVIR Green Hills Biotechnology
- Batavia Biosciences
- Bavarian Nordic
- BD Biosciences
- Beijing Minhai Biotechnology
- Beijing Zhifei Lvzhu Biopharmaceutical
- Bharat Biotech
- Bielefeld University
- Bio Farma
- BioCell
- BioConnection
- Biofabri
- Biological E
- Biological Industries
- BioMARC
- BioReliance
- BlueWillow Biologics
- Boehringer Ingelheim
- Boryung Pharmaceutical
- BravoVax
- Bryllan
- CanSino Biologics
- Capricorn Scientific
- Catalent Biologics
- Cellca (Acquired by Sartorius)
- CellGenix
- CEVEC Pharmaceuticals
- Charles River Laboratories
- Chengdu Zenmindes Biotechnology
- CiMaas
- CJ HealthCare
- Cobra Biologics
- Codagenix
- Commonwealth Serum Laboratories (CSL)
- Creative Biolabs
- Curevo Vaccine
- Cytiva
- CyTuVax
- Daiichi Sankyo
- DanDrit Biotech
- DCPrime
- Dendreon
- Elios Therapeutics
- Emergent BioSolutions
- Fisher Scientific (Acquired by Thermo Fisher Scientific)
- FluGen
- FUJIFILM Wako Pure Chemicals
- GC Pharma
- GeneOne Life Science
- GlaxoSmithKline
- Gradalis
- HALIX
- Heat Biologics
- Hilleman Laboratories
- Hookipa Biotech
- Icahn School of Medicine at Mount Sinai
- IDT Biologika
- ILiAD Biotechnologies
- Immunicum
- ImmunoCellular Therapeutics
- Immutep
- Indian Immunologicals
- Inovio Pharmaceuticals
- Institut National de la Santé et de la Recherche Médicale (INSERM)
- Insud Pharma
- Intermountain Life Sciences
- Intervet
- InVitria
- Invitrogen
- Irvine Scientific Sales (Acquired by FUJIFILM)
- IS JAPAN (Acquired by FUJIFILM)
- Janssen Pharmaceuticals
- Jianshun Biosciences
- JN International Medical
- JW CreaGene
- Kansas State University
- KBI Biopharma
- Kiromic
- Leland Stanford Junior University
- LG Chem
- LimmaTech Biologics
- Lonza
- Luina Bio
- Massachusetts Institute of Technology
- MassBiologics
- Medicago
- Medigen Vaccine Biologics
- Medigene
- Meissa Vaccines
- Merck
- Meridian Life Science
- MilliporeSigma
- MinervaX
- Moderna
- MolecuVax
- Northwest Biotherapeutics
- Nova Immunotherapeutics
- Novartis
- Novasep
- Novavax
- NPO Petrovax Pharm
- Ology Bioservices
- Oncobiomed
- OPM Biosciences
- Osivax
- Oxford Biomedica
- Pall Corporation
- Panacea Biotec
- Patheon Viral Vector Services
- PDC*line Pharma
- Pfizer
- Premas Biotech
- Prestige BioPharma
- ProBioGen
- Regeneus
- Research Institute at Nationwide Children's Hospital
- Sanaria
- Sanofi Pasteur
- Saronic Biotechnology
- Sartorius
- Scandinavian Biopharma
- Seqirus
- Serum Institute of India
- Shanghai Bovax Biotechnology
- Shenzhen Hornetcorn Biotechnology
- Shenzhen Kangtai Biological Products
- Sigma-Aldrich
- SK Bioscience
- SOTIO
- Symbiosis Pharmaceutical Services
- Takeda
- TapImmune
- Tella
- Tessa Therapeutics
- TeutoCell
- Themis Bioscience
- Thermo Electron
- Thermo Fisher Scientific
- Thousand Oaks Biopharmaceuticals
- TNCbio
- Unity Lab Services
- University of California
- University of Pennsylvania
- University of Texas
- USHEALTH
- Vaccinogen
- Vaccitech
- Valneva
- Vaxart
- Vaxine
- Vibalogics
- Waisman Biomanufacturing
- WuXi Biologics
- Xell
- XEME Biopharma
Methodology
LOADING...